PPCB

Company Overview — What Does Propanc Biopharma, Inc. Do?

Propanc Biopharma, Inc., a biopharmaceutical company, focuses on the development of cancer treatments for patients with pancreatic, ovarian, and colorectal cancer in Australia. Its lead product is PRP, a formulation that is in preclinical phase of development designed to enhance the anti-cancer effects of multiple enzymes acting synergistically. The company has a research collaboration with University of Jaén to commence the POP1 joint drug discovery program. The company was formerly known as Propanc Health Group Corporation and changed its name to Propanc Biopharma, Inc. in April 2017. Propanc Biopharma, Inc. was incorporated in 2007 and is based in Camberwell, Australia. Propanc Biopharma, Inc. (PPCB) is classified as a micro-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. and employs approximately 1 people. With a market capitalization of $2M, PPCB is one of the notable companies in the Healthcare sector.

Propanc Biopharma, Inc. (PPCB) Stock Rating — Avoid (April 2026)

As of April 2026, Propanc Biopharma, Inc. receives a Avoid rating with a composite score of 20.3/100 and 1 out of 5 stars from the Blank Capital Research quantitative model.PPCB ranks #4,383 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Propanc Biopharma, Inc. ranks #817 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

PPCB Stock Price and 52-Week Range

Propanc Biopharma, Inc. (PPCB) currently trades at $0.10. The stock lost $0.00 (2.4%) in the most recent trading session. The 52-week high for PPCB is $9.36, which means the stock is currently trading -99.0% from its annual peak. The 52-week low is $0.11, putting the stock -14.1% above its annual trough. Recent trading volume was 1.8M shares, reflecting moderate market activity.

Is PPCB Overvalued or Undervalued? — Valuation Analysis

Propanc Biopharma, Inc. (PPCB) carries a value factor score of 9/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 0.23x, versus the sector average of 2.75x.

At current multiples, Propanc Biopharma, Inc. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

Propanc Biopharma, Inc. Profitability — ROE, Margins, and Quality Score

Propanc Biopharma, Inc. (PPCB) earns a quality factor score of 17/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -639.4%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -442.3% versus the sector average of -33.1%.

Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

PPCB Debt, Balance Sheet, and Financial Health

Propanc Biopharma, Inc. has a debt-to-equity ratio of 1.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 2.13x, indicating strong short-term liquidity. Total debt on the balance sheet is $55,000.

PPCB has a beta of 1.01, meaning it is roughly in line with the broader market in terms of price volatility. The stability factor score for Propanc Biopharma, Inc. is 18/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

Propanc Biopharma, Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, Propanc Biopharma, Inc. reported revenue of $0 and earnings per share (EPS) of $-0.30. Net income for the quarter was $-67M. Operating income came in at $-66M.

In Q2 2026, Propanc Biopharma, Inc. reported revenue of $0 and earnings per share (EPS) of $-0.30. Net income for the quarter was $-3M. Operating income came in at $-4M.

In Q1 2026, Propanc Biopharma, Inc. reported revenue of $0 and earnings per share (EPS) of $-0.39. Net income for the quarter was $-5M. Operating income came in at $-5M.

In Q1 2025, Propanc Biopharma, Inc. reported revenue of $0 and earnings per share (EPS) of $-0.39. Net income for the quarter was $-5M. Operating income came in at $-5M.

Over the past 8 quarters, Propanc Biopharma, Inc. has experienced revenue contraction from $0 to $0. Investors analyzing PPCB stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

PPCB Dividend Yield and Income Analysis

Propanc Biopharma, Inc. (PPCB) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

PPCB Momentum and Technical Analysis Profile

Propanc Biopharma, Inc. (PPCB) has a momentum factor score of 16/100, signaling weak relative price performance. Stocks with low momentum scores have historically tended to continue underperforming in the near term. The investment factor score is 25/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 57/100 reflects moderate short selling activity.

PPCB vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, Propanc Biopharma, Inc. (PPCB) ranks #817 out of 838 stocks based on the Blank Capital composite score. This places PPCB in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing PPCB against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full PPCB vs S&P 500 (SPY) comparison to assess how Propanc Biopharma, Inc. stacks up against the broader market across all factor dimensions.

PPCB Next Earnings Date

No upcoming earnings date has been announced for Propanc Biopharma, Inc. (PPCB) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy PPCB? — Investment Thesis Summary

The quantitative profile for Propanc Biopharma, Inc. suggests caution. The quality score of 17/100 flags below-average profitability. The value score of 9/100 indicates premium valuation. Momentum is weak at 16/100, a headwind for near-term performance. High volatility (stability score 18/100) increases portfolio risk.

In summary, Propanc Biopharma, Inc. (PPCB) earns a Avoid rating with a composite score of 20.3/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on PPCB stock.

Related Resources for PPCB Investors

Explore more research and tools: PPCB vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare PPCB head-to-head with peers: PPCB vs AZN, PPCB vs SLGL, PPCB vs VMD.